Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...

Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...

As this year’s respiratory syncytial virus (RSV) season approaches, Beyfortus makers Sanofi and AstraZeneca are making ...

Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €100.00.

With a new production line, Sanofi aims to keep it and partner AstraZeneca’s drug Beyfortus in fully supply this RSV season.

(Reuters) -Sanofi and partner AstraZeneca have received approval from the U.S. Food and Drug Administration for a manufacturing line for their preventive respiratory syncytial virus (RSV ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and ...

Hoechst and Rhône-Poulenc Rorer were the two companies that merged to form Aventis. Despite Sanofi-Synthélabo’s size, the company found itself forced to partner with larger pharmaceutical ...

SBI Magnum Midcap Fund - Direct (G) 217.19 3,18,972 1.01 SBI Magnum Midcap Fund - Direct (IDCW) 217.19 3,18,972 1.01 Aditya Birla SL Frontline Equity Fund (G) 167.89 2,46,566 0.55 Aditya Birla SL ...

We want to do the right thing. We never stop trying to improve the lives of patients, the planet, and our employees. The Sanofi of today is built on a heritage of turning the impossible into the ...